THERADIAG

Combined General Meeting of May 14, 2020 - Seite 2

Votes casted by shareholders by post or online for the first General Meeting will remain valid, and will be counted for the second call of the General Meeting.

Voting will only take place remotely, prior to the General Meeting and in accordance with the specific conditions for general meetings in closed session. Shareholders will not be able to submit draft amendments or new resolutions during the General Meeting.

Due to the impossibility to ask questions during the General Meeting, Theradiag recommends that shareholders who wish to do so send their written questions, as from the second notice of the General Meeting, together with a certificate of account registration, and this by favouring sending them by e-mail ([e-mail]). They will be taken into account upon receipt at the latest on the fourth working day preceding the date of the General Meeting, i.e. by midnight, Paris time, on Friday 19 June 2020.

Finally, shareholders will have the opportunity to participate in the Shareholders’ Meeting, convened for a second time by conference call held in French, details of which will be communicated at a later date. The presentation will be made available on the Company's website at the beginning of the General Meeting under the dedicated section https://www.theradiag.com/category/presentations-financieres/.

For any question regarding the voting arrangements, please email the Investor Relations department at [e-mail].

Furthermore, following its most recent release on April 22, 2020, the Company provides an update on the specific activities linked to the Covid-19.

Covid-19 serology testing

Theradiag confirms it continues its commitment to the fight against Covid-19. With public authorities extending the scope of testing to serology, Theradiag, a specialist in immunology, is deploying its expertise in antibody dosage testing to help fight the pandemic.

Theradiag is currently developing and will market as soon as possible two different types of serology tests. The Company will produce rapid diagnostic tests as well as tests based on its ELISA (Enzyme Linked ImmunoSorbent Assay) technology. At the end of April, the Company initiated a validation procedure for serology test kits with the National Reference Center in Paris (CNR) and other external assessors. This procedure is ongoing.